Protagonist Therapeutics (PTGX) Gains from Investment Securities (2015 - 2025)

Protagonist Therapeutics has disclosed Gains from Investment Securities across 8 years of filings, most recently posting $39.1 million for Q4 2025.

• Gains from Investment Securities for Q4 2025 came in at $39.1 million, down 3.92% year-over-year; the trailing twelve-month figure through Dec 2025 was $39.1 million (down 3.93% YoY), and the FY2025 annual result was $7.7 million, down 1.89% from the prior year.
• Gains from Investment Securities came in at $39.1 million for Q4 2025 at Protagonist Therapeutics, up from -$5000.0 in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $40.7 million in Q4 2024 to a low of -$5000.0 in Q1 2025.
• The 4-year median for Gains from Investment Securities is $6.4 million (2022), against an average of $11.9 million.
• Across the five-year window, Gains from Investment Securities tumbled 67.71% in 2023 and surged 413.76% in 2024, its largest moves.
• Protagonist Therapeutics' Gains from Investment Securities stood at $6.4 million in 2022, then climbed by 22.99% to $7.9 million in 2023, then soared by 413.76% to $40.7 million in 2024, then dropped by 3.92% to $39.1 million in 2025.
• The last three Gains from Investment Securities figures came in at $39.1 million (Q4 2025), -$5000.0 (Q1 2025), and $40.7 million (Q4 2024), per Business Quant data.